Registry Platform Ovarian and Endometrial Cancer

iOMEDICO AG1,975 enrolled

Overview

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.

SMARAGD is a national, prospective, open-label, longitudinal, non-interventional multicenter cohort study (tumour registry platform) to describe treatment in routine clinical practice of ovarian, fallopian tube, primary peritoneal and endometrial patients in routine care in Germany. The registry will follow patients for up to three years with the aim to identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Health-related quality of life (HRQoL) will be evaluated for up to three years.

Study Type

OBSERVATIONAL

Enrollment

1,975

Conditions

Ovarian Cancer Endometrial Cancer Ovary Neoplasm Endometrial Neoplasms Carcinoma, Ovarian

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer): * patients with FIGO stage IIb-IV OC who are starting systemic treatment or * patients with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent/relapsed disease. * Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy. * Signed and dated informed consent (IC): * Patients participating in PRO module: IC before first therapy cycle * Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle Exclusion Criteria: * newly diagnosed early-stage OC (FIGO stage I-IIa) * Low grade mOC OR * Early-stage EC (FIGO stage I-II)